A detailed history of Geode Capital Management, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,844,714 shares of ACAD stock, worth $42.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,844,714
Previous 2,793,237 1.84%
Holding current value
$42.1 Million
Previous $51.6 Million 10.49%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$14.62 - $18.42 $752,593 - $948,206
51,477 Added 1.84%
2,844,714 $46.2 Million
Q1 2024

May 13, 2024

BUY
$17.79 - $30.86 $1.8 Million - $3.12 Million
101,085 Added 3.75%
2,793,237 $51.6 Million
Q4 2023

Feb 13, 2024

BUY
$20.78 - $31.77 $2.36 Million - $3.61 Million
113,770 Added 4.41%
2,692,152 $84.3 Million
Q3 2023

Nov 13, 2023

BUY
$20.84 - $33.47 $1.75 Million - $2.81 Million
84,044 Added 3.37%
2,578,382 $53.7 Million
Q2 2023

Aug 11, 2023

BUY
$17.8 - $25.65 $1.85 Million - $2.67 Million
104,071 Added 4.35%
2,494,338 $59.7 Million
Q1 2023

May 15, 2023

BUY
$16.32 - $20.92 $1.48 Million - $1.9 Million
90,768 Added 3.95%
2,390,267 $45 Million
Q4 2022

Feb 13, 2023

BUY
$14.2 - $18.63 $1.11 Million - $1.46 Million
78,348 Added 3.53%
2,299,499 $36.6 Million
Q3 2022

Nov 14, 2022

BUY
$14.11 - $18.27 $848,956 - $1.1 Million
60,167 Added 2.78%
2,221,151 $36.3 Million
Q2 2022

Aug 12, 2022

SELL
$13.01 - $27.22 $539,147 - $1.13 Million
-41,441 Reduced 1.88%
2,160,984 $30.4 Million
Q1 2022

May 13, 2022

BUY
$20.94 - $27.5 $801,436 - $1.05 Million
38,273 Added 1.77%
2,202,425 $53.3 Million
Q4 2021

Feb 11, 2022

BUY
$16.79 - $27.09 $2.4 Million - $3.87 Million
143,000 Added 7.08%
2,164,152 $50.5 Million
Q3 2021

Nov 12, 2021

SELL
$15.78 - $24.77 $854,455 - $1.34 Million
-54,148 Reduced 2.61%
2,021,152 $33.6 Million
Q2 2021

Aug 13, 2021

BUY
$19.4 - $27.42 $11.8 Million - $16.7 Million
608,790 Added 41.51%
2,075,300 $50.6 Million
Q1 2021

May 12, 2021

BUY
$25.02 - $54.99 $1.18 Million - $2.6 Million
47,298 Added 3.33%
1,466,510 $37.8 Million
Q4 2020

Feb 12, 2021

BUY
$41.04 - $56.79 $3.65 Million - $5.05 Million
88,896 Added 6.68%
1,419,212 $75.9 Million
Q3 2020

Nov 13, 2020

SELL
$36.42 - $57.0 $1.46 Million - $2.29 Million
-40,187 Reduced 2.93%
1,330,316 $54.9 Million
Q2 2020

Aug 13, 2020

SELL
$39.26 - $52.73 $14 Million - $18.9 Million
-357,567 Reduced 20.69%
1,370,503 $66.4 Million
Q1 2020

May 14, 2020

BUY
$31.65 - $46.87 $3.39 Million - $5.02 Million
107,011 Added 6.6%
1,728,070 $73 Million
Q4 2019

Feb 13, 2020

BUY
$36.21 - $51.4 $4.66 Million - $6.61 Million
128,565 Added 8.61%
1,621,059 $69.3 Million
Q3 2019

Nov 12, 2019

BUY
$22.22 - $44.01 $103,589 - $205,174
4,662 Added 0.31%
1,492,494 $53.7 Million
Q2 2019

Aug 14, 2019

BUY
$23.32 - $28.12 $1.54 Million - $1.86 Million
66,169 Added 4.65%
1,487,832 $39.8 Million
Q1 2019

May 14, 2019

BUY
$16.17 - $27.38 $2.86 Million - $4.84 Million
176,724 Added 14.2%
1,421,663 $38.2 Million
Q4 2018

Feb 13, 2019

BUY
$14.32 - $22.92 $2.54 Million - $4.07 Million
177,701 Added 16.65%
1,244,939 $20.1 Million
Q3 2018

Nov 13, 2018

BUY
$13.03 - $21.81 $815,743 - $1.37 Million
62,605 Added 6.23%
1,067,238 $22.2 Million
Q2 2018

Aug 14, 2018

BUY
$15.07 - $22.34 $1.49 Million - $2.21 Million
99,084 Added 10.94%
1,004,633 $15.3 Million
Q1 2018

May 15, 2018

BUY
$22.47 - $32.33 $799,302 - $1.15 Million
35,572 Added 4.09%
905,549 $20.3 Million
Q4 2017

Feb 13, 2018

BUY
$26.84 - $39.14 $666,893 - $972,511
24,847 Added 2.94%
869,977 $26.2 Million
Q3 2017

Nov 14, 2017

BUY
$29.49 - $38.37 $1.61 Million - $2.1 Million
54,720 Added 6.92%
845,130 $31.8 Million
Q2 2017

Aug 14, 2017

BUY
N/A
790,410
790,410 $22 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.39B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.